Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Pumitamig · BNT-327, BMS-986545

Bispecific antibody · Antagonist of PD-L1 (CD274) and VEGF-A · developed by BRISTOL MYERS SQUIBB

Phase 2/3 Most advanced trial
BMY Developer
1 Registered trials

What is Pumitamig?

Pumitamig is a bispecific antibody that simultaneously binds PD-L1 and VEGF-A. It blocks PD-L1 interaction with PD-1 to restore T-cell immunity and prevents VEGF-A from activating VEGF receptors to inhibit angiogenesis. It is studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BNT-327, BMS-986545, PM8002
Drug type
Bispecific antibody
Targets
PD-L1 (CD274), VEGF-A, PD-1 (PDCD1) (binding partner it blocks), VEGF receptor (FLT1) (binding partner it blocks)
Mechanism
Antagonist of PD-L1 (CD274) and VEGF-A
Pathways
PD-1 signaling, VEGF/VEGFR signaling, angiogenesis, T-cell activation
Therapy area
Oncology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
QEA2EG9S3E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06712316 Phase 2/3 Non-small Cell Lung Cancer Recruiting BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung Cancer

Other drugs acting on CD274 / VEGFA

ABP 938 FDA approved Aflibercept FDA approved Bevacizumab FDA approved Durvalumab FDA approved Acasunlimab Phase 3 AN4005 Phase 1 AXN-2510 Phase 1 CDX-527 Phase 1 Cenopodlin Phase 1 CTX-8371 Phase 1 Enristomig Phase 1 Ivonescimab Phase 3

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Pumitamig

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.